论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Lin M, Chen B
Received 31 December 2017
Accepted for publication 8 March 2018
Published 30 April 2018 Volume 2018:12 Pages 1009—1017
DOI https://doi.org/10.2147/DDDT.S161199
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Palas Chanda
Peer reviewer comments 2
Editor who approved publication: Professor Manfred Ogris
Abstract: Acute myeloid leukemia (AML) is a heterogeneous hematologic
malignancy, characterized by the clonal expansion of myeloid blasts in the
peripheral blood, bone marrow, and/or other tissues. The new drugs used for
treating AML are facing a big challenge, and the candidates include cytotoxic
drugs, targeted small-molecule inhibitors, and monoclonal antibodies. In recent
years, active research has focused on several new agents for including them in
the large antileukemic drug family. This review aims to introduce some of these
new drugs and highlights new advances made in the old drugs, mainly in the last
5 years.
Keywords: acute myeloid
leukemia, new drug therapies, refractory/relapsed AML, 2017 NCCN guideline